Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an update.
Roquefort Therapeutics announced that its ordinary shares will be marked ex-entitlement for Unlisted Redeemable Non-Voting Shares as of December 1, 2025. Shareholders and convertible loan note holders registered by November 28, 2025, are eligible to receive these shares, with further details on the entitlement ratio and issuance to be announced later.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on acquiring exclusive license rights to AO-252, a novel drug targeting the TACC3 protein for cancer treatment. The company is in the process of completing a transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc.
Average Trading Volume: 2,733,210
Technical Sentiment Signal: Sell
Current Market Cap: £3.23M
Find detailed analytics on ROQ stock on TipRanks’ Stock Analysis page.